---
title: "Jupiter Bioscience Ltd (JUPITER) — Share Price, Financials & Analysis"
symbol: "JUPITER"
company: "Jupiter Bioscience Ltd"
canonical: "https://tapetide.com/stocks/JUPITER"
sector: "Commodities"
industry: "Chemicals & Petrochemicals"
generated_at: "2026-09-13T19:39:59.401Z"
---

# Jupiter Bioscience Ltd (JUPITER)

Canonical page: https://tapetide.com/stocks/JUPITER

## Company

- **Sector:** Commodities
- **Industry:** Chemicals & Petrochemicals
- **Macro Sector:** Commodities
- **Stock Type:** EQUITY
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** jupiterbioscience.com

## About

Jupiter Bioscience Limited manufactures drug intermediates, specialty and fine chemicals, bulk drugs, and nutraceuticals primarily in India. The company offers aminoacids and its derivatives, including Fmoc-, Boc-, and Z-protected aminoacids, as well as side chain protected aminoacids.

## Latest Price

## Key Insights

### Strengths

- Stock is trading at 0.03 times its book value
- Company has delivered good profit growth of 22.8% CAGR over last 5 years

### Weaknesses

- Tax rate seems low
- Company has a low return on equity of 9.58% over last 3 years.

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| net income growth | 21% | 20% | 23% |
| revenue growth | 42% | 29% | 29% |

## Financial Statements

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 |
| --- | --- | --- | --- | --- | --- | --- |
| Sales | 91 | 121 | 154 | 178 | 233 | 331 |
| Expenses | 49 | 70 | 86 | 90 | 113 | 185 |
| Operating Profit | 42 | 51 | 68 | 88 | 119 | 146 |
| OPM % | 46 | 42 | 44 | 50 | 51 | 44 |
| Other Income | 0 | 0 | 1 | 2 | 0 | 0 |
| Interest | 7 | 8 | 13 | 19 | 26 | 29 |
| Depreciation | 12 | 16 | 22 | 33 | 44 | 59 |
| Profit before tax | 23 | 27 | 34 | 38 | 49 | 58 |
| Tax % | 21 | 25 | 14 | 12 | 13 | 12 |
| Net Profit | 18 | 20 | 30 | 33 | 42 | 51 |
| EPS in Rs | — | 20.51 | 16.4 | 20.48 | 26.33 | 8.23 |
| Dividend Payout % | 12 | 11 | 12 | 10 | 9 | 13 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 |
| --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 9 | 10 | 18 | 16 | 18 | 65 |
| Reserves | 107 | 161 | 291 | 319 | 390 | 789 |
| Borrowings | 114 | 180 | 200 | 301 | 427 | 455 |
| Other Liabilities | 22 | 21 | 30 | 34 | 37 | 56 |
| Total Liabilities | 252 | 371 | 539 | 670 | 873 | 1364 |
| Fixed Assets | 96 | 143 | 241 | 317 | 408 | 513 |
| CWIP | 42 | 81 | 123 | 146 | 217 | 259 |
| Investments | 1 | 1 | 1 | 10 | 18 | 301 |
| Other Assets | 114 | 146 | 174 | 198 | 231 | 291 |
| Total Assets | 252 | 371 | 539 | 670 | 873 | 1364 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 32 | 18 | 48 | 68 | 92 | 118 |
| Cash from Investing Activity | -57 | -105 | -163 | -143 | -220 | -514 |
| Cash from Financing Activity | 25 | 88 | 115 | 74 | 133 | 395 |
| Net Cash Flow | 0 | 1 | 0 | -1 | 5 | -2 |
| Free Cash Flow | -10 | -86 | -114 | -64 | -114 | -90 |
| CFO/OP | 88 | 50 | 76 | 82 | 84 | 89 |

### Ratios

| Item | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 |
| --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 81 | 87 | 94 | 102 | 92 | 90 |
| Inventory Days | 190 | 316 | 354 | 418 | 346 | 221 |
| Days Payable | 34 | 35 | 34 | 51 | 50 | 29 |
| Cash Conversion Cycle | 237 | 368 | 413 | 470 | 388 | 282 |
| Working Capital Days | 122 | 190 | 213 | 239 | 225 | 187 |
| ROCE % | — | 12 | 11 | 10 | 10 | 8 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 1 / 7 / 11

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 1.15 | Sell |
| EMA (10) | 1.13 | Sell |
| SMA (20) | 1.14 | Sell |
| EMA (20) | 1.15 | Sell |
| SMA (50) | 1.22 | Sell |
| EMA (50) | 1.21 | Sell |
| SMA (100) | 1.34 | Sell |
| EMA (100) | 1.32 | Sell |
| SMA (200) | 1.51 | Sell |
| EMA (200) | 1.52 | Sell |

### Oscillators — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 44.62 | Neutral |
| MACD (12,26,9) | -0.02 | Buy |
| Stochastic (14,3,3) | 40.74 | Neutral |
| ADX (14) | 10.99 | Neutral |
| Williams %R (14) | -75 | Neutral |
| ATR (14) | 0.08 | High Volatility |
| ROC (12) | -1.8 | Sell |
| Stoch RSI (14) | 36.42 | Neutral |
| UO (7,14,28) | 44.76 | Neutral |

## Filings & Documents

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2011 from bse](https://www.bseindia.com/bseplus/AnnualReport/524826/5248260311.pdf) |
| from bse | [Annual Report 2010 from bse](https://www.bseindia.com/bseplus/AnnualReport/524826/5248260310.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:39:59.401Z.